Lunaphore’s first product reaches the market
07.02.2019
Share this article
EPFL spin-off, Lunaphore released on 7 February 2019 it’s “rapid screening test for cancer”.
Lunaphore has acquired the CE marking for its product and will be commercializing it across Europe as of today.
“Lunaphore’s tumor analysis system LabSatTM detects and classifies tumors more quickly and reliably than existing solutions. The microfluidic system, developed through doctoral research at EPFL, is designed for use by research labs, pharmaceutical companies and hospitals. It hits the market today.”
Read EPFL’s full article in English